Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login



Anti-epileptic drug valproate linked to around 4,000 birth defects in France

Women who took the drug in pregnancy were four times more likely than women in the general population to give birth to babies with severe congenital malformations.

valproate cleftlip ss april 17

Source: Shutterstock

Cleft palate is one of the severe birth malformations caused by taking valproate in pregnancy, French authorities have concluded

The epilepsy drug valproate has been responsible for between 2,150 and 4,100 severe birth defects in children born in France since it was launched in 1967, according to a study by French medicine and health authorities.

The severe birth malformations include spina bifida, cleft palate and defects of the heart and genital organs. The risk of autism and developmental problems was also found to be higher.

The joint report from the French drug regulator (L’Agence nationale de sécurité du médicament et des produits de santé (ANSM)) and the national health insurance administration (la Caisse Nationale de l’Assurance Maladie des Travailleurs Salariés (CNAMTS)) says that between 1967 and 2016, between 64,100 and 100,000 pregnancies in France were exposed to valproate, resulting in 41,200 to 75,300 live births.

The vast majority of the birth malformations occurred in children born to women who took the drug as a treatment for epilepsy while pregnant. These women were four times more likely than women in the general population to give birth to babies with severe congenital malformations.

From the late 1970s, valproate was also prescribed in France to treat bipolar disorder, and these women were twice as likely as the general population to give birth to babies with severe congenital malformations.

The report suggests that the difference in raised risk for the two conditions may be the result of women treated for bipolar disorder having a lower exposure to valproate than those treated for epilepsy, because non-adherence and treatment interruptions are more frequent in treatment for bipolar disorder than they are for epilepsy.

Citation: The Pharmaceutical Journal URI: 20202641

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • MCQs in Clinical Pharmacy

    MCQs in Clinical Pharmacy

    Four practice tests, each with 80 practice-oriented MCQs. Assess your knowledge of clinical issues, evaluative and analytical skills.

    £25.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • valproate cleftlip ss april 17
  • child with autism undergoing assessment

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.